The “top 200 drugs” in the United States are overwhelmingly medications for chronic conditions: blood pressure pills, cholesterol-lowering statins, diabetes treatments, antidepressants, acid reducers, and pain relievers. The list shifts year to year as new drugs climb and older ones lose patent protection, but the broad pattern has been remarkably stable for decades. What has changed recently is the dramatic entrance of GLP-1 receptor agonists like semaglutide, which became the single highest-spending drug in the country in 2024, reshaping both the revenue picture and the therapeutic landscape.
Chronic Disease Drugs Run the List
If you scan any version of the top 200 by prescription volume, the same therapeutic classes show up over and over. Antihypertensives, antiplatelet agents, diuretics, and cholesterol-lowering drugs form the backbone of cardiovascular prescribing, which is the single largest category by number of prescriptions filled each year.1PubMed Central. Prescribing trends and rational drug use patterns in cardiovascular patients: A cross-sectional observational study Lisinopril, amlodipine, atorvastatin, and metoprolol are fixtures. These are almost all available as inexpensive generics, which partly explains their volume: they treat extremely common conditions at low cost.
Diabetes medications claim a large share as well. Metformin, a drug that has been in use for over 60 years, remains the standard first-line treatment for type 2 diabetes because of its ability to lower blood sugar effectively, its favorable safety profile, and its low cost.2PubMed Central. Metformin and Its Benefits for Various Diseases A large systematic review and meta-analysis confirmed that metformin holds up well as initial therapy when compared against other glucose-lowering options, with benefits for blood sugar control, body weight, and cardiovascular mortality relative to older alternatives like sulfonylureas.3PubMed. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis When patients need something beyond metformin alone, sulfonylureas remain the most frequently added second-line drug according to about half of surveyed physicians, though newer classes like SGLT-2 inhibitors and GLP-1 receptor agonists are gaining ground rapidly.4PubMed Central. Factors Influencing the Choice of Glucose-Lowering Medications Among Physicians Treating Patients With Type 2 Diabetes
The GLP-1 Surge
No drug class has rewritten the top 200 rankings more dramatically in recent years than GLP-1 receptor agonists. Total U.S. spending on GLP-1 RAs grew by more than 500% between 2018 and 2023, rising from about $14 billion to nearly $72 billion.5PubMed Central. Spending on Glucagon-Like Peptide-1 Receptor Agonists Among US Adults The pace accelerated: after averaging roughly 34% growth per year from 2018 to 2022, spending jumped by 62% in a single year from 2022 to 2023.6PubMed Central. Spending on Glucagon-Like Peptide-1 Receptor Agonists Among US Adults By 2024, semaglutide (sold as Ozempic and Wegovy) was the top drug in the nation by expenditure, followed by tirzepatide and adalimumab.7American Journal of Health-System Pharmacy. National trends in prescription drug expenditures and projections for 2025
This is unusual. Most top-200 drugs by volume are cheap generics; they dominate the list because hundreds of millions of prescriptions are filled. Semaglutide dominates by spending because it is expensive and because demand has exploded as the drugs found a second life in weight management beyond their original diabetes indication. The split between volume leaders and spending leaders is one of the most important features of any top 200 list, and GLP-1 drugs have widened that gap considerably.
Pain Management’s Shift Away From Opioids
The pain-management drugs on the top 200 tell a story of deliberate change. Between 2006 and 2016, NSAID-related visits in U.S. outpatient settings rose steadily, from about 8% to nearly 10% of all ambulatory care visits, with a sharper increase after 2012. Acetaminophen visits roughly doubled over the same period. Researchers noted that this rise coincided temporally with declining opioid prescribing.8The Journal of Pain. Trends in Prescribing of Non-steroidal Anti-inflammatory Medications in the US Ambulatory Care Setting From 2006 to 2016
The trend continued after 2016. An analysis of more than 16,000 orthopedic surgeons found that opioid prescriptions fell by about 4.4% per year between 2016 and 2020, while NSAID prescriptions rose by about 3.3% per year.9Journal of the American Academy of Orthopaedic Surgeons. National Trends in Orthopaedic Pain Management from 2016 to 2020 NSAIDs accounted for over 57% of all pain-medication prescription days in that study, compared with under 29% for opioids.10Journal of the American Academy of Orthopaedic Surgeons. National Trends in Orthopaedic Pain Management from 2016 to 2020 Ibuprofen, naproxen, and meloxicam are now firmly in the top 200 by prescription count, while opioids like hydrocodone and oxycodone have slid in relative rank as prescribers pull back.
Antidepressants and Their Staying Power
SSRIs dominate mental health prescribing. In one three-year outpatient analysis, SSRIs accounted for nearly 64% of all antidepressant prescriptions, with sertraline alone making up about a quarter of the total.11PubMed Central. Uncovering antidepressant prescription patterns: a three-year analysis of outpatient trends Sertraline, escitalopram, and fluoxetine have been top-200 mainstays for years. They are all available as generics, making them affordable, and clinicians are comfortable with their side-effect profiles compared with older tricyclic antidepressants. Bupropion, which works through a different mechanism and is also used for smoking cessation, has climbed steadily and frequently appears in the top 50 by volume. The broader picture is that antidepressant use has grown substantially over the past two decades, driven by rising diagnosis rates for depression and anxiety as well as expanded use for off-label conditions like chronic pain.
Antibiotics and the Stewardship Problem
Antibiotics remain among the most frequently prescribed drugs in outpatient settings, with azithromycin, amoxicillin, amoxicillin-clavulanate, ciprofloxacin, and cephalexin at the top of the list.12PubMed Central. Outpatient Antibiotic Prescription Trends in the United States: A National Cohort Study The concern is not that these drugs are prescribed but how often they are prescribed unnecessarily. The COVID-19 pandemic provided a natural experiment: among patients who received an antibiotic within a week of a COVID-19 or COVID-like diagnosis, roughly 23% received an antibiotic deemed “inappropriate,” and another 39% received one classified as only “potentially appropriate.” Azithromycin was the most common choice, prescribed to anywhere from 22% to 45% of patients across different cohorts.13PubMed Central. Antibiotic prescribing trends in the US during the first 11 months of the COVID-19 pandemic
Antimicrobial stewardship efforts are slowly bending the curve, but azithromycin and amoxicillin remain enormous-volume drugs partly because they are prescribed for conditions where evidence of benefit is thin. Their presence in the top 200 reflects both genuine need and a persistent overprescribing habit.
Proton Pump Inhibitors and the Overuse Dilemma
Omeprazole and pantoprazole are perennially in the top 20 by prescription volume. The use of proton pump inhibitors in U.S. adults doubled from about 4% in 1999 to nearly 8% by 2012.14Gastroenterology. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association Clinical guidelines recommend taking them at the lowest effective dose for the shortest reasonable duration, typically four to eight weeks for most acid-related conditions. In practice, the pattern is the opposite: a global systematic review found that nearly two-thirds of PPI users were on higher-than-recommended doses, and about a quarter had been taking them continuously for a year or longer. Among those long-term users, over a quarter had been on PPIs for more than three years.15PubMed Central. Proton pump inhibitor use: systematic review of global trends and practices
The drugs work well for acid reflux and ulcer prevention, and their side effects for short courses are mild. But extended use has been linked in observational research to risks including kidney problems, bone fractures, and intestinal infections. The gap between guideline-recommended duration and actual use is one of the starkest examples of “prescribing inertia” in modern medicine: once started, PPIs tend not to be stopped, and they accumulate on the top 200 list as a result.
Inhaled Medications for Asthma and COPD
Inhaled drugs are the foundation of treatment for asthma and chronic obstructive pulmonary disease. The two main classes are inhaled corticosteroids and bronchodilators, often combined in a single inhaler device.16PubMed. Prescription of inhalers in asthma and COPD: towards a rational, rapid and effective approach Albuterol (salbutamol), the go-to rescue inhaler, is one of the highest-volume drugs in any country. Longer-acting maintenance medications like fluticasone-salmeterol combinations have also been consistent top-200 entries.
In COPD specifically, single-inhaler combinations of an inhaled corticosteroid and a long-acting bronchodilator saw the fastest rate of growth in a 19-year Canadian population study, increasing at nearly 12% per year and accounting for over half the total cost of COPD inhalers by 2015.17PubMed Central. Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada Triple therapy combining three drug classes in one device has been growing as well, reflecting a trend toward simplified regimens to improve adherence. These combination inhalers often carry brand-name prices that make them significant contributors to total drug spending, even when their prescription counts are lower than pills like lisinopril or metformin.
Which Top Drugs Send People to the Emergency Room
The drugs most commonly prescribed are not necessarily the most dangerous, but high volume means that even low rates of adverse events add up to large absolute numbers. In U.S. emergency departments, anticoagulants, antibiotics, and diabetes medications together accounted for nearly 47% of all visits for outpatient adverse drug events.18PubMed Central. US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014 The specific problems were predictable: bleeding from blood thinners, allergic reactions from antibiotics, and dangerously low blood sugar from insulin and other diabetes drugs.
For older adults, the picture is even more concentrated. An earlier study found that just three medications — warfarin, insulin, and digoxin — were responsible for about a third of emergency visits for adverse drug events in people 65 and older. The risk of an ER visit from those three drugs was 35 times greater than the risk from the medications formally classified as “always potentially inappropriate” for elderly patients.19PubMed. Medication use leading to emergency department visits for adverse drug events in older adults The irony is that warfarin and insulin are often essential, but their narrow dosing windows make them inherently risky, and they are prescribed to millions of people. A Korean multicenter study found a similar pattern globally, with blood thinners, diabetes drugs, and antibiotics high on the list of adverse-event culprits.20PLoS ONE. Adverse drug events leading to emergency department visits: A multicenter observational study in Korea
Polypharmacy in Older Adults
The top 200 drugs matter partly because many people take multiple drugs from that list simultaneously. An analysis of over two billion physician office visits in the U.S. found that roughly 65% involved some degree of polypharmacy. The largest single category was “major polypharmacy” — patients on many concurrent medications — which accounted for about 37% of all visits by older adults.21PLoS ONE. Polypharmacy prevalence in older adults seen in United States physician offices from 2009 to 2016 When you combine antihypertensives, a statin, metformin, a PPI, an SSRI, and an occasional antibiotic, a single patient may be taking five or six top-200 drugs at once. Each additional medication increases the chance of drug interactions, side effects, and the kind of emergency department visits described above. Medication reviews and deprescribing — deliberately stopping drugs that are no longer needed — have become a growing focus precisely because the top 200 list keeps getting longer per patient, not just per country.
How Cost and Formulary Placement Shape What Gets Prescribed
The drugs that make the top 200 by volume are heavily influenced by insurance formularies. When a drug sits on a preferred tier with a low copay, patients fill their prescriptions more consistently. Research has shown that patients prescribed a generic medication had adherence rates about 13% higher than patients who received a nonpreferred brand-name drug, and even a preferred brand beat a nonpreferred one by roughly 9%.22JAMA Internal Medicine. The Implications of Choice: Prescribing Generic or Preferred Pharmaceuticals Improves Medication Adherence for Chronic Conditions The mechanism is straightforward: lower out-of-pocket costs make people more likely to pick up and continue their medication.
Even small copay differences matter. One study of electronic prescribing with formulary decision support found that for each dollar increase in monthly copayment, medication adherence dropped measurably.23PubMed Central. Effect of electronic prescribing with formulary decision support on medication tier, copayments, and adherence For expensive conditions like Alzheimer’s disease, where a nonpreferred drug like galantamine can cost a Medicare beneficiary over $100 per month out of pocket, the formulary tier placement directly affects whether a patient continues treatment.24PubMed Central. Assessing the Equitable Use of Formulary Drug Tier Systems: Consequences for Geriatric Patient Population Access and Accessible Medication This creates a feedback loop: drugs that land on preferred tiers get prescribed more, generate more volume, and entrench themselves in the top 200, while clinically equivalent alternatives with worse formulary positioning fade from use.
Racial and Ethnic Disparities in Who Gets What
The top 200 list looks different depending on who is doing the filling. A large cross-sectional study of prescription use across all 50 states found that per capita pharmaceutical use was highest among White populations and lowest among Asian or Pacific Islander and Hispanic populations. After adjusting for age and the actual prevalence of disease, Black populations showed substantially lower prescription fills relative to what their disease burden would predict.25PubMed Central. Prescription Drug Utilization and Spending by Race, Ethnicity, Payer, Health Condition, and US State In other words, the gap is not just about who is sicker. Even accounting for who needs medication, Black patients appear to receive less of it.
Interestingly, when it comes to potentially inappropriate medications, the pattern flips. White Medicare beneficiaries had the highest rates of high-risk medication use and the highest rates of harmful drug-disease interactions, including among those with dementia and those with a history of falls. Black, Hispanic, and Asian or Pacific Islander beneficiaries all had lower rates of potentially inappropriate prescribing.26JAMA Network Open. Racial and Ethnic Differences in Potentially Inappropriate Medication Use Among Medicare Beneficiaries This does not mean those groups are better served. Lower rates of inappropriate drugs alongside lower rates of appropriate drugs suggest that underutilization, rather than careful selection, may be driving the numbers.
Biologics Are Reshaping the Revenue Rankings
The top 200 by sales revenue increasingly features biologic drugs — large, complex molecules like monoclonal antibodies rather than traditional small-molecule pills. Adalimumab (Humira), used for autoimmune conditions, was the world’s best-selling drug for years. Biologics command higher prices: the median peak annual global revenue for a biologic was about $3.8 billion compared with roughly $1.4 billion for a small-molecule drug.27PubMed Central. Revenue Differences Between Top-Selling Small-Molecule Drugs and Biologics in Medicare – Section: Results Over the typical life cycle of a drug, biologics accumulated far more cumulative revenue as well. This revenue gap has grown over time and explains why the spending-based top 200 looks increasingly different from the volume-based top 200. A single biologic prescribed to a relatively small number of patients can outspend a generic statin prescribed to tens of millions.
The market exclusivity window for top-selling drugs has also been lengthening. Among 437 top-selling drugs studied, the median period of market exclusivity was about 12.5 years overall, but that figure climbed over time — drugs losing exclusivity in 2012 had a median of nearly 15 years before generic competition arrived, compared with under 10 years for those losing exclusivity in 2000.28JAMA Internal Medicine. Variations in Time of Market Exclusivity Among Top-Selling Prescription Drugs in the United States Biologics, which face higher barriers to generic (biosimilar) entry, tend to enjoy even longer periods without competition. This is one reason the spending side of the top 200 keeps climbing even as many volume leaders remain cheap generics.
Advertising’s Fingerprints on the List
The United States and New Zealand are the only two countries that allow direct-to-consumer advertising of prescription drugs. That advertising shapes which drugs patients ask for and, consequently, which drugs get prescribed. Reviews of the evidence consistently find that direct-to-consumer advertising increases the likelihood that patients will request a specific brand-name drug by name and that physicians will prescribe it.29PubMed Central. Direct-to-Consumer Drug Advertisement and Prescribing Practices: Evidence Review and Practical Guidance for Clinicians A systematic review found that this advertising is associated with increased prescribing of advertised products and has a substantial impact on both patient requests and physician prescribing confidence.30BMJ Quality & Safety. Benefits and harms of direct to consumer advertising: a systematic review
The effect is not all negative. Advertising can prompt people to seek care for untreated conditions, and some advertised drugs are genuinely the best option. But it also drives prescriptions toward more expensive brand-name products when cheaper generics would work equally well. The drugs that spend the most on advertising — newer brand-name medications in high-demand therapeutic areas — tend to climb the revenue-based rankings faster than their clinical merits alone would predict. When you see a newer drug shoot up the top 200 by spending, advertising dollars are often part of the explanation alongside genuine clinical innovation.
The Environmental Footprint of High-Volume Prescribing
One consequence of billions of prescriptions filled each year is that pharmaceutical compounds end up in the water supply. Drugs are excreted by patients, flushed as expired medications, and incompletely removed by wastewater treatment facilities. The rising global use of medications has caused concentrations in water bodies to increase substantially.31PubMed Central. Pharmaceutical Pollution in Aquatic Environments: A Concise Review of Environmental Impacts and Bioremediation Systems Low levels of pharmaceutical compounds have been detected in aquatic environments worldwide, though the human and ecological health risks of that low-dose environmental exposure remain largely unknown for most compounds, in part because there are so many of them.32PubMed Central. Prioritizing environmental risk of prescription pharmaceuticals
The drugs most likely to cause environmental concern are those prescribed at high volume with high excretion rates: antibiotics, hormonal contraceptives, antidepressants, and anti-inflammatory drugs. Antibiotic residues are a particular worry because of their potential to promote resistance in environmental bacteria. For now, the concentrations found in treated water are typically far below therapeutic doses, but the sheer scale of global prescribing means the problem is growing, and regulators in Europe have begun requiring environmental risk assessments for newly approved medications. In the U.S., drug-take-back programs and improved wastewater treatment are the primary policy responses, though neither fully solves the problem of a pharmaceutical supply that grows larger every year.